These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25025694)

  • 1. Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome.
    Kafian S; Mobarrez F; Wallén H; Samad B
    Platelets; 2015; 26(5):467-73. PubMed ID: 25025694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
    Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
    Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
    Becatti M; Fiorillo C; Gori AM; Marcucci R; Paniccia R; Giusti B; Violi F; Pignatelli P; Gensini GF; Abbate R
    Atherosclerosis; 2013 Dec; 231(2):392-400. PubMed ID: 24267257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome.
    Lee S; Hizoh I; Kovacs A; Horvath Z; Kiss N; Toth-Zsamboki E; Kiss RG
    Platelets; 2016; 27(2):159-67. PubMed ID: 26247099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
    Johnston LR; Larsen PD; La Flamme AC; Michel JM; Simmonds MB; Harding SA
    Int J Cardiol; 2013 Aug; 167(3):995-9. PubMed ID: 22465351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary intervention.
    Ratcovich H; Holmvang L; Johansson PI; Parup Dridi N
    Platelets; 2016; 27(1):51-8. PubMed ID: 25927944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment.
    Kalantzi KI; Dimitriou AA; Goudevenos JA; Tselepis AD
    Platelets; 2012; 23(2):121-31. PubMed ID: 21806493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived microparticles during and after acute coronary syndrome.
    Skeppholm M; Mobarrez F; Malmqvist K; Wallén H
    Thromb Haemost; 2012 Jun; 107(6):1122-9. PubMed ID: 22371053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvesicles from patients with acute coronary syndrome enhance platelet aggregation.
    Kafian S; Wallén H; Samad BA; Mobarrez F
    Scand J Clin Lab Invest; 2019 Nov; 79(7):507-512. PubMed ID: 31502883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
    Selhorst G; Schmidtler F; Ott A; Hitzke E; Tomelden J; Antoni D; Hoffmann E; Rieber J
    Platelets; 2019; 30(3):341-347. PubMed ID: 29521570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity.
    Zhang L; Li Y; Yang BS; Li L; Wang XZ; Ge ML; Jing QM; Ma YY; Wang G; Liu HW; Zhao X; Wang B; Xu K; Han YL
    Chin Med J (Engl); 2018 Mar; 131(5):508-515. PubMed ID: 29483383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
    Holm M; Dalén M; Tornvall P; van der Linden J
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):577-84. PubMed ID: 24614428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice.
    Fefer P; Beigel R; Rosenberg N; Shechter M; Gannot S; Varon D; Savion N; Hod H; Matetzky S
    Platelets; 2015; 26(2):127-31. PubMed ID: 24617352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
    Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
    Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.